2024-09-18 - Analysis Report
## Eli Lilly and Company (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Company is a leading pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products, including insulin and other diabetes treatments, oncology therapies, and treatments for autoimmune disorders.

**1. Performance Analysis:**

* **Cumulative Return:** LLY has a cumulative return of 544.25%, significantly outperforming the S&P 500 (VOO) with a return of 89.02%.
* **Relative Outperformance:** LLY's current outperformance is 455.23% compared to VOO. This places LLY at the 94.46th percentile of its historical performance range relative to VOO, indicating a strong historical performance.

**2. Recent Price Action:**

* **Closing Price:** $923.54
* **5-day Moving Average:** $920.88
* **20-day Moving Average:** $935.79
* **60-day Moving Average:** $897.42

The stock is currently trading slightly below its 20-day moving average, suggesting potential short-term downward pressure. However, the stock is still above its 60-day moving average, indicating a potential long-term upward trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 41.19.  An RSI below 50 suggests that the stock may be oversold, indicating potential for a rebound.
* **PPO (Percentage Price Oscillator):** -0.49.  A negative PPO value indicates that the stock's price is declining faster than its moving average, suggesting potential bearish momentum.
* **Delta_Previous_Relative_Divergence:** -1.52. A negative value indicates a recent short-term downward trend in relative outperformance.
* **Expected Return:** 26.77%. This represents the potential 5-year return based on current investment conditions.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings for the quarter ended August 8, 2024, were $3.29 per share, exceeding analyst expectations. Revenue also beat estimates, coming in at $11.30 billion. This strong performance reflects continued demand for Lilly's products and the company's ability to manage its operations effectively.

**5. Summary:**

LLY has a strong historical performance with a significantly higher cumulative return than the S&P 500. Recent price action suggests potential short-term downward pressure, but long-term trends remain positive. Technical indicators suggest a potential oversold condition and bearish momentum, while the expected return remains strong. Recent earnings results exceeded expectations, demonstrating continued strength in the company's business. 

**6. Overall, LLY continues to be a strong performer with a solid track record. While current technical indicators suggest potential short-term downside, the long-term outlook remains positive, supported by a strong earnings performance and a solid product portfolio.**